Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Emerging viral infections

John R. Su, MD, PhD

Departments of Pathology and Preventive Medicine, Dartmouth-Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03756, USA

“Emerging infections” have been defined as infections (including drug-resistant infections) that have newly appeared, that have appeared previously but are expanding in incidence and geographic range, or that threaten to increase in the near future [1,2]. This article focuses on nine emerging viral infectious agents.

Drug-resistant HIV

Because monotherapy with antiretroviral drugs rapidly leads to the development of resistant HIV [3], current antiretroviral therapies use multiple drugs. Nonetheless, drug-resistant HIV is increasingly problematic. Part of this problem stems from the prevalence of recombination and mutation observed in HIV [4–6]. Not surprisingly, drug-resistant HIV is increasingly reported in the literature [5].

The prevalence of drug-resistant HIV varies dramatically with geographic location—for example, rates in the United States may approach 23%, whereas in Australia reported rates are as low as 3.3% [5,7,8]. The exact mechanisms of drug resistance vary as well. Multiple mutations in the RT and PR genes of HIV that are associated with drug resistance have been identified, and studies continue to characterize these mutations [9–11]. Current clinical guidelines recommend resistance typing in HIV patients before beginning antiretroviral therapy [12,13]. For the moment, antiretroviral therapy guided by resistance typing appears to improve patient outcomes [14–16].

Filovirus

Filoviruses include Marburg virus (MBOV) and Ebola virus (EBOV) and cause filoviral viral hemorrhagic fever (VHF). MBOV is currently the only...
virus in its group, whereas EBOV contains four subtypes: Sudan, Zaire, Reston, and Ivory Coast [17–19]. The natural reservoir for these viruses remains unknown, although arthropods do not appear to be the reservoir [20,21].

The hallmark of filoviral VHF is disseminated intravascular coagulopathy (DIC), with death usually occurring after 6 to 9 days. Recent studies observe that lymphoid macrophages and peripheral monocytes infected with EBOV exhibit increased secretion of tissue factor, which could trigger the extrinsic coagulation pathway and cause DIC [22]. This model is corroborated by studies of DIC in other contexts (eg, sepsis), where DIC also correlates with decreased protein C and improves with administration of recombinant protein C [23–25].

Regarding vaccines, more recent efforts have included recombinant vaccinia virus, recombinant filoviral proteins, and naked DNA [26–28]. A recent report using adenoviral vectors encoding EBOV glycoprotein led to a rapid cell-mediated response to EBOV challenge in cynomolgus macaque monkeys [29]. Regarding antiviral treatments, initial reports using S-adenosylhomocysteine hydrolase inhibitors demonstrated a protective effect in mouse models of EBOV infection [30,31]. Recombinant factor VII/tissue factor inhibitor has been successfully used to treat EBOV VHF in rhesus macaque monkeys [22]. To date, a clinically proven antiviral drug for human filoviral VHF remains elusive, and supportive care remains the mainstay of treatment.

Diagnosis of filoviral VHF has included such approaches as isolation of the virus in cell culture, enzyme immunoassay (EIA), ELISA, and reverse-transcriptase polymerase chain reaction (RT-PCR) [32–35]; such work must be done under biosafety level-4 (BSL-4) conditions. Filoviruses seem to demonstrate seasonality, with outbreaks tending to occur early in the wet season [36].

Filoviruses share “Category A” classification (meaning high risk of use) with smallpox, anthrax, and plague [37], and speculation exists that filoviruses have already been adapted for use as weapons of mass destruction [38].

**Hantavirus**

The causative agent of the prototypic hemorrhagic fever with renal syndrome (HFRS)—Korean hemorrhagic fever—was first described in 1978 [39]. 1993 saw the discovery of the Sin Nombre virus (SNV) and hantavirus pulmonary syndrome (HPS) [40,41]. As of this writing, multiple hantaviruses have been described; as a class, hantaviruses cause HFRS, HPS, or manifestations of both diseases.

Like other bunyaviruses, the hantavirus genome consists of three segments of single-stranded, negative-sense RNA housed in a helical nucleocapsid. This segmented genome has raised the question of genetic variation in
hantaviruses. Genetic drift clearly plays a role [42,43]. The role of genetic shift is less clear. Studies have demonstrated that diploid strains are unstable, but reassorted virus has been reported with genetic variants of SNV and Dobrava virus [44,45]. Notably, homologous recombination—the first instance of such recombination in negative-sense RNA viruses—was first described in Tula virus, and later in Dobrava virus [45,46]. Nonetheless, human infections appear to be more due to encroachment upon hantavirus host habitats (or vice versa) than to fundamental changes in the viruses themselves [41,47].

Most hantaviruses are carried by a single rodent species [48]. The geographic distribution of specific hantaviruses—hence the clinical diseases they cause—is tied to their host’s natural habitat: hantaviruses native to the Eastern hemisphere or “Old World” are associated with HFRS, while hantaviruses native to the Americas are associated with HPS [49,50]. HFRS and HPS will therefore be discussed separately. In both cases, infection occurs by means of inhalation of dried rodent excreta, although laboratory-borne and in utero infections have also been reported [50–53]. Human-to-human transmission of hantaviruses does not occur, with the notable exception of HPS caused by Andes virus [54,55].

HFRS is classically defined by four phases [49,50]. (1) It begins with a febrile phase or prodrome of influenza-like symptoms lasting 3 to 5 days after a 2- to 3-week incubation period; sudden, extreme albuminuria can occur the fourth day of the prodrome. (2) A hypotensive phase follows, marked by DIC that lasts from a few hours to days, reflecting an extensive vascular leak syndrome [56]. (3) An oliguric phase then follows, with death usually due to renal failure; this phase can last from a few days to 2 weeks. (4) Patients who recover progress into a diuretic phase and convalescence, both of which can last months. The severity of HFRS depends on the specific causative hantavirus [49,50].

Management of HFRS involves treating shock with pressors and fluids, as well as albumin and dialysis, which can reduce mortality [50]; volume management is highly important. Intravenous ribavirin, administered within the first 4 days of illness, has demonstrated benefit [57].

HPS also appears to follow phases: after a 14- to 17-day incubation period, a similar febrile phase of 3 to 5 days’ duration occurs; thrombocytopenia may be present, but other stigmata of coagulopathy are usually absent. Cardiopulmonary involvement follows the febrile phase; most patients are hospitalized during this phase. A triad of thrombocytopenia, immature granulocytes, and circulating lymphoblasts can be seen on a peripheral blood smear [56,58]. Renal dysfunction and myositis can also occur in some cases. Patients who survive typically recover from pulmonary edema and shock in 3 to 6 days, followed by diuresis of excess fluid. HPS can prove remarkably lethal: HPS from SNV infection carries a 40% to 60% mortality rate [49,58].

Because the differential diagnosis for HPS also includes bacterial causes, patients should receive antibiotic therapy consistent with therapy for
community-acquired pneumonia and sepsis, including *Yersinia pestis* [56]. Aggressive respiratory support is indicated, as are packed red blood cells (to maintain oxygen-carrying capacity) as appropriate. In contrast to HFRS, therapy for HPS with ribavirin has not demonstrated much benefit [59,60].

After inhalation, viral entry into cells for at least some hantaviruses appears mediated by β3 integrins; such integrins are found on endothelial cells and platelets [61,62]. A vigorous immune response has been noted that includes T-lymphocytes and numerous cytokines [63,64]. This immune response is thought to cause the vascular leak noted in both HFRS and HPS; a similar reaction can be seen in cancer patients receiving high-dose interleukin-2 [65].

Laboratory diagnosis of hantavirus infection usually rests upon IgM-detecting enzyme-linked immunosorbent assays or RT-PCR; RT-PCR can distinguish among the Old World hantaviruses [66,67]. Tissue and serum specimens should be handled at BSL-3 or -4 levels. Virus isolation is difficult and not typically done in clinical microbiology laboratories [56]. In addition, hantavirus maintained in cell culture accumulates mutations not present in its wild type state [42,68].

**Henipavirus**

The 1994 outbreak of a highly lethal respiratory syndrome among horses in Australia led to the discovery of a novel paramyxovirus later named Hendra virus (HeV) [69]. In 1999, a similar outbreak in pigs caused an outbreak of human encephalitis in Malaysia with a case-fatality rate approaching 40% [70]; the causative agent was identified as a distinct but Hendra-like virus later named Nipah virus (NiV) [70]. Molecular studies demonstrate that these two viruses define a new genus of paramyxovirus, *Henipavirus* [71].

Of the two reported human cases of HeV, one patient died after an acute respiratory disease and the other patient died of leptomeningitis more than a year after an initial bout of acute aseptic meningitis [72,73]. Otherwise, HeV is primarily a pathogen of horses [74]. In horses, the disease manifests as fever and respiratory distress with copious, frothy (and, in some cases, blood-tinged) nasal discharge.

In its initial emergence, NiV led to the deaths of 105 humans and the eventual culling of over a million pigs [75]. Human NiV infection led to an encephalitic syndrome marked by fever, headache, drowsiness, and disorientation that could rapidly (within 48 hours) progress to coma and death; the virus appeared to be contracted by contact with infected pigs [76,77]. Follow-up studies suggest that NiV can lead to a remitting-relapsing pattern of neurologic disease as well [78]. In pigs, NiV caused an acute respiratory illness with fever and sometimes nervous signs. A recent outbreak of Nipah virus in Bangladesh also appeared encephalitic, but was epidemiologically distinct; contact with pigs was not a major factor [211]. This epidemiologic distinction has raised speculation about a third henipavirus [79].
Fruit bats—also called “flying foxes”—appear to be the natural reservoir for these viruses, with an endemic region spanning from the eastern Australian coast to Pakistan [75]. No human-to-human spread has been demonstrated for either HeV or NiV, although pathology confirms that the virus was probably spread among pigs via respiratory routes [74].

The diagnosis of henipavirus infection has involved viral culture using Vero cells, RT-PCR, immunohistochemistry, and both indirect and capture enzyme-linked immunosorbent assays for IgG and IgM [70,80]. Cytopathic effect (CPE) shows as syncytia that detach from the substrate, leaving punctuate holes in the cell monolayer. Immunohistochemistry can be safely performed on a wide variety of formalin-fixed tissues, as primary pathology occurs in the vascular endothelium. Ideally, such work should be done under BSL-4 conditions [80]. Irradiation, heat inactivation, and detergent treatment have been used to make laboratory work-up safer where viral viability is not a concern [80].

Because of its lethality, concerns exist about the possible use of NiV as a biological weapon; indeed, the Centers for Disease Control and Prevention (CDC) lists it as a category C agent [81,82]. However, ribavirin was used open-label in the initial NiV outbreak and seemed to demonstrate some benefit [83], and an experimental vaccine in hamsters appears promising [84].

**Human metapneumovirus**

The subfamily *Pneumovirinae* consists of two genera: Pneumovirus (typified by human respiratory syncytial virus [hRSV]), and Metapneumovirus. Until 2001, the sole member of the Metapneumovirus genus was the Avian pneumovirus (APV). That year, van den Hoogen et al [85] cultured a paramyxovirus-like virus that exhibited cytopathic effect indistinguishable from hRSV. Further characterization demonstrated that this new virus was more closely related to APV than hRSV, and the virus was therefore named human metapneumovirus (hMPV) [85].

Retrospective serologic studies suggest that hMPV has been circulating among humans for almost 50 years [85]. Since its initial discovery, hMPV has been reported globally [86–89]. hMPV causes disease by itself, but can be isolated with other viruses, most commonly hRSV [89–92]. Whether coinfection causes more severe disease is unclear [87,92].

hMPV causes lower-tract respiratory disease in humans of all ages [93,94]. A flu-like syndrome of malaise, myalgia, and fever has also been reported in association with hMPV [95]. Like hRSV, the disease appears more severe in young children [90,94]. Preliminary evidence suggests a winter seasonal pattern similar to hRSV [87,94,96]. Recent reports indicate that hMPV is a leading cause of respiratory illness in children [94,96].

Genetic studies suggest four subgroups of hMPV [97]. In terms of laboratory diagnosis, investigators have used a variety of respiratory specimens—nose, throat, and nasopharyngeal swabs and washes, and
bronchoalveolar lavage fluid—but mostly rely on RT-PCR for purposes of identification [89].

Influenza

In 1997, the first direct transmission of avian influenza virus to humans was observed with an H5N1 strain [98]. Other H5 influenza viruses continue to emerge [99], including H5N2 mutants with attenuated immunogenicity (but not diminished virulence) [100]. Indeed, H5N1 reemerged in Southeast Asia in early 2004 [101,102]. A similar situation occurred in the Netherlands with an H7N7 strain, causing an outbreak of viral conjunctivitis and one human fatality (where the virus had mutations not present in virus from the other cases) [103,104]. These infections seem to correlate with mutations in the H5 and H7 viruses [105–107].

Another concern is the increasing prevalence of H6 and H9 strains in domestic poultry worldwide [108,109]. H9N2 strains can infect humans and cocirculate with H3N2 strains in pigs [110,111]; indeed, H9 and H3 strains appear similar even by radiographic crystallography [112].

The H1N1 strain of the 1918 to 1919 influenza pandemic has gained particular notoriety; recent studies have demonstrated the feasibility of developing an effective vaccine against its possible reemergence [113].

Poxviruses

Monkeypox

Monkeypox virus (MPV) was first isolated in 1958, and the first human MPV infection was documented in 1970 [114,115]. Endemic to the rain-forested regions of Africa, MPV had never been seen outside of Africa until last year, when the Western Hemisphere’s first case was reported in a 3-year-old girl in Wisconsin [116]. By the end of this outbreak, 72 cases were identified in six states, with no fatalities or cases of secondary transmission. The original source of MPV appears to have been at least one species of African rodent with which prairie dogs had contact [116]. The CDC and the US Food and Drug Administration have banned the further import of these African rodents, although concern exists that MPV may already have established itself in the rodent population of the United States [117].

Human MPV infection manifests after a 10- to 14-day incubation period, with a prodrome of fever and malaise that lasts 2 days; development of lymphadenopathy occurs before the rash. The rash spreads in a centrifugal pattern and becomes generalized, with lesions resolving over a period of 14 to 21 days [118]. Extracutaneous manifestations include secondary skin/soft tissue infections, pneumonitis, ocular complications, and encephalitis [119]. Reported case-fatality rates range from zero (in the United States) to 17% (in Africa) [117,120].
The clinical diagnosis of MPV infection is difficult, partially because the rash of MPV infection can resemble the rashes seen in smallpox, chickenpox, and even herpes simplex virus [121,122]. The lymphadenopathy of MPV infection appears specific to MPV; a history of contact with exotic animals is also helpful in making the diagnosis [116,117,120]. Laboratory diagnosis of MPV also can be difficult: only sequence analysis can distinguish among the orthopoxviruses, but this technique takes time, and reliable, rapid tests are still needed [122,123]. Recent reports using real-time PCR and oligonucleotide microarray techniques appear promising [124–126]. Currently, laboratory diagnosis depends on cell culture or chick chorioallantoic membrane isolation in conjunction with DNA-based assays [123]. Cutaneous tissue (eg, vesicular material) and blood can be used for diagnostic purposes [127]. The reader is referred to the CDC for more detailed information on specimen collection and transport [82]. MPV can be safely handled under BSL-2 conditions, but if variola virus is suspected, referral of specimens to the state public health laboratory for analysis at the CDC is prudent [82].

Both pre- and postexposure vaccination with vaccinia virus can prevent MPV infection [127]. No data are available regarding the efficacy of antiviral treatment for MPV, although cidofovir and vaccinia immune globulin can be used for patients with severe MPV infection or patients with MPV who are immunodeficient [127,128].

Concern exists about the potential use of MPV as a weapon of bioterrorism. While human case-fatality rates tend to be low, there is debate on the questions of how efficiently aerosol transmission leads to secondary cases and whether such transmission would be more lethal [129,130]. Evidence indicates that MPV causing human infections has remained stable over the last few decades, and that MPV and variola virus evolved independently—suggesting that wild-type MPV is unlikely to evolve into a variola-like virus [131,132]. Nonetheless, some experts cite the results of Jackson et al [133] with IL-4–modified ectromelia as evidence of how MPV could be genetically modified into a highly lethal biological weapon.

Tanapox

Tanapox virus (TPV) infection in humans has historically been rare. Recent cases have been reported, however [134,135]. TPV is harbored in nonhuman primates and is transmitted to humans mostly by arthropods [136]. Human TPV disease is typically mild, with an onset of mild fever (38°C to 39°C), headache, and myalgia. One to a few papules develop, forming nodules with regional lymphadenopathy that resolve about 6 weeks after the onset of clinical disease [137]. This presentation differs markedly from smallpox, whose onset includes high fever and multiple lesions. No vaccine or treatment currently exists for TPV infection, but historically the disease is self-limiting [135].
TPV is a member of the Yatapoxvirus genus, along with Yaba monkey tumor virus (YMTV) and Yaba-like disease virus (YLDV). These members are all closely related [138,139]. Recent studies demonstrate that TPV is > 98% identical to YLDV at the nucleotide level [140]; also, human YLDV infection is clinically identical to TPV infection [141,142]. These latter observations have led some investigators to conclude that TPV and YLDV are strains of the same virus [138].

Smallpox

Smallpox has been extensively described in the literature [119,143,144]. Recent studies have focused on antiviral treatment, vaccination, and rapid testing for variola virus (VV). Some studies show promise regarding the use of cidofovir and other investigational drugs to treat smallpox, but human clinical data is lacking [128,145]. Efforts to prepare against possible use of VV as a weapon have therefore focused on vaccination, but complications of such vaccination give some observers pause [146–149]. As a partial solution, research into new vaccines for VV continues [147]. Allegations persist that unauthorized stocks of VV exist, and that biological weapons research with VV continues today [38,150]. To develop rapid tests for VV, current efforts have gravitated toward real-time PCR and DNA microarray techniques [125,126,151,152].

Severe acute respiratory syndrome

In November 2002, cases of a new pulmonary disease, later named severe acute respiratory syndrome (SARS), were noted in the Guandong Province of China. The causative agent was identified in April 2003 as a novel coronavirus (SARS-CoV) [153,154]. By the end of the first outbreak of SARS-CoV in July 2003, SARS had afflicted over 8000 people worldwide with over 770 fatalities [155]. Because human coronaviruses cycle periodically [156], the reappearance of SARS could be anticipated, and indeed new cases of SARS were identified early in 2004 [157].

The animal reservoir and origin of SARS-CoV are not known, although the virus has been isolated from civet cats and other wild animals [155]. SARS-CoV is genetically distinct from the other three classes of coronavirus, but shares homology with both Group II and Group III coronaviruses (Fig. 1) [153,154]. Recent studies suggest a mixed mammalian and avian lineage, possibly by means of recombination [158]. During the epidemic spread of SARS in 2002 to 2003, other strains were also cocirculating in Guandong [159], raising questions about whether one strain of SARS-CoV is more transmissible than another.

SARS appears to be spread by droplets or fomites by means of contact with mucous membranes (directly or indirectly) [155]. In some instances, “super spreaders”—a few cases causing a disproportionate number of
successive transmissions—have been noted [160,161]. SARS-CoV has been isolated from multiple specimen types, including blood, suggesting systemic spread through the body [162,163]. Clinical features of SARS include an incubation period of 2 to 10 days with a mean of 6 days [155,164]. Initial symptoms include fever (>38°C), malaise, myalgia, and chills or rigors [155,164], with respiratory symptoms and sometimes watery diarrhea occurring later in the course of illness [155]. SARS is less commonly associated with upper respiratory symptoms like rhinorrhea or sore throat [155]. Regarding severity, one third of patients improve spontaneously, whereas 20% to 30% of patients will require intensive care, most of which will need mechanical ventilation [164,165]. In autopsy specimens, diffuse alveolar damage is seen in various levels of progression and severity (Fig. 2).
Age (older than 65) and coexisting illness predict a worse course. Death is attributed to respiratory failure, multiple organ failure, or comorbidity with existing medical conditions [155,164]. Some studies suggest that interferons and corticosteroids may improve the clinical course of SARS [166,167], but data from randomized placebo-controlled trials are still needed to demonstrate efficacy; in addition, the possible long-term sequelae of such therapy are unclear [168]. Investigators are currently studying the efficacy of antiviral drugs as well [169].

Fig. 2. (A,B) Hematoxylin and eosin stains of lung tissue from a SARS patient, demonstrating diffuse alveolar damage and multinucleated syncytial cells. (From Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, et al. A novel coronavirus associated with Severe Acute Respiratory Syndrome. N Engl J Med 2003;348:1953; with permission.)

Fig. 3. Cytopathic effect of SARS-CoV in Vero E6 cells, showing foci of cell rounding, cell refractiveness, and occasional syncytia. (From Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, et al. A novel coronavirus associated with Severe Acute Respiratory Syndrome. N Engl J Med 2003;348:1951; with permission.)
Before the identification of SARS-CoV, clinical diagnosis of SARS was based largely on exposure history and case definitions of “suspect” and “probable” cases [170]. RT-PCR methodologies were rapidly developed to assist in the laboratory diagnosis of SARS [163,171,172]. In cell culture, SARS-CoV demonstrates CPE in the Vero E6 cell line as foci of cell rounding and cell refractiveness, with occasional syncytia (Fig. 3) [154]. However, real-time RT-PCR assays currently represent the mainstay of laboratory diagnosis; nasopharyngeal aspirates and swabs are the typical specimens of such tests. DNA microarray techniques may also be appearing in the near future [173]. Convalescent sera can be used to establish SARS infection retrospectively using whole virus immunoassays [155]. Biosafety protocols for handling materials containing SARS-CoV exist [174] and should be adhered to strictly: laboratory-acquired infections with SARS-CoV have occurred in Singapore and Taipei (the latter case in a BSL-4 laboratory) [175,176].

West Nile virus

West Nile virus (WNV) was first isolated in Uganda in 1937 [177] and first emerged in the United States in 1999. Since that time, the number of cases of WNV in the United States has continued to climb [178]. The American strain of WNV appears to have originated from the Middle East, although the specific mechanism of introduction into the United States remains undetermined [179].

WNV is a member of the family Flaviviridae, genus Flavivirus; serologically, WNV is a member of the Japanese encephalitis virus antigenic complex. WNV is maintained in a cycle of transmission from mosquito to bird and back to mosquito. Although Culex species mosquitoes appear to be the primary vector [180], WNV has been found in other species (and in ticks in the Eastern Hemisphere) [181]. North American bird species can serve as hosts for WNV, and bird migration appears to play a role in the maintenance and propagation of the virus in nature [182,183]. Natural mammalian infection with WNV has been documented only in horses and humans, both of which are considered dead-end hosts. However, case reports of transmission in utero, via breast-feeding, and through accidental percutaneous laboratory exposure, organ transplantation, and blood transfusion have been reported [184–190]. The last two routes have led to revision of blood donor deferral criteria and nucleic acid testing of donated blood [191,192].

In humans, about 20% of cases of infection with WNV lead to clinical disease, typically after an incubation period of 2 to 6 days. Uncomplicated cases begin with a sudden onset of fever ( > 39°C), headache, myalgia, and often gastrointestinal symptoms; a maculopapular rash and lymphadenopathy may also occur in half of these patients [193,194]. Such cases usually last less than a week, although a lingering fatigue is common [181].
Almost 1% of patients infected with WNV develop more severe illness, ranging from uncomplicated viral meningitis to debilitating flaccid paralysis [195]. Age (over 50 years) is the most important risk factor for central nervous system (CNS) complications, which include tremors, myoclonus, and seizures [196,197]. Patients with WNV-associated flaccid paralysis are relatively young with asymmetric weakness and no sensory involvement. CNS involvement carries a 10% to 14% mortality (WNV encephalitis appears particularly lethal [197,198]) and long-term morbidity: almost two thirds of patients with WNV encephalitis have lingering neurologic difficulties 1 year after their acute illness [197,199].

Initial replication of WNV is thought to occur in the skin and regional lymph nodes, seeding the reticuloendothelial system; the resulting secondary viremia may then seed the CNS, with adhesion and neuroinvasion mediated by the E protein [200,201]. Pathologic CNS findings include diffuse inflammation of the brainstem, with microglial nodules and areas of perivascular inflammation in the proximal brainstem [200,202]. In animal infections of WNV, anterior horn cells showed degeneration and neuronal cell death, with WNV antigen localized mainly within the gray matter of the spinal cord. This finding provides a pathologic explanation for WNV-associated flaccid paralysis [203,204]; similar findings were recently reported for a fatal human case of WNV [205]. The affinity of WNV for these tissues remains unexplained.

Serology with acute and convalescent sera remains the primary means of laboratory confirmation of WNV infection; a panel of other flaviviruses also should be included in the comparison [181]. A presumptive diagnosis can be made with enzyme immunoassays and immunofluorescent antibody assays for anti-WNV IgM, although such IgM can persist in patients several months after acute infection [206]. Isolation of WNV from clinical specimens has proved difficult; molecular assays exist, but because of the low magnitude and transient viremia in humans, they are of limited clinical value [181,207].

A number of antiviral treatments for WNV show promise in vitro, including nucleoside analogues (eg, ribavirin), interferon-α, and human immunoglobulin, but no clinical data support their use in patients [198,208–210]. For the moment, supportive management with ventilatory support and treatment for cerebral edema is the key measure; the benefits of prophylactic steroids or osmotic agents remain unknown. Human vaccines for WNV are not currently available, but are under research.

Summary

Today’s emerging viral infections will be superseded by yet other viral infections in the future. We see hints of how these future viral infections will emerge in the infections covered by this article: by encroaching on previously unvisited habitats (eg, hantaviruses), by air travel (eg, SARS),
and by accidental importation (eg, monkeypox). The example of SARS demonstrates not only how quickly emerging viral infections can spread but also how quickly they can be identified and contained with motivated cooperation. Likewise, research into vaccines and antiviral treatments for these viruses must continue.

References

[1] Morse SS. Factors in the emergence of infectious diseases. Emerg Infect Dis 1995;1(1):7–15.
[2] Emerging infections: microbial threats to health in the United States. Washington, DC: National Academy Press; 1992.
[3] Darbyshire J, Foulkes M, Peto R, Duncan W, Babiker A, Collins R, et al. Immediate versus deferred zidovudine (AZT) in asymptomatic or mildly symptomatic HIV infected adults. Cochrane Database Syst Rev 2000;3:CD002039.
[4] Yu H, Jetz AE, Ron Y, Preston BD, Dougherty JP. The nature of human immunodeficiency virus type 1 strand transfers. J Biol Chem 1998;273(43):28384–91.
[5] Ammaranond P, Cunningham P, Oelrichs R, Suzuki K, Harris C, Leas L, et al. Rates of transmission of antiretroviral drug resistant strains of HIV-1. J Clin Virol 2003;26(2):153–61.
[6] Mansky LM, Temin HM. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 1995;69(8):5087–94.
[7] Sabin CA. The changing clinical epidemiology of AIDS in the highly active antiretroviral therapy era. AIDS 2002;16(Suppl 4):S61–8.
[8] Harrigan PR, Montaner JS, Wegner SA, Verbiest W, Miller V, Wood R, et al. Worldwide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing. AIDS 2001;15(13):1671–7.
[9] International AIDS Society-USA Resistance Testing Panel. Antiretroviral resistance mutations [revised April 2001]. HIV Clin Trials 2001;2(4):346–55.
[10] Blaise P, Clevenbergh P, Vaira D, Moutschen M, Dellamonica P. HIV resistance to antiretroviral drugs: mechanisms, genotypic and phenotypic resistance testing in clinical practice. Acta Clin Belg 2002;57(4):191–201.
[11] Lafeuillade A, Poggi C, Hittinger G, Chadapaud S. Phenotypic and genotypic resistance to nucleoside reverse transcriptase inhibitors in HIV-1 clinical isolates. HIV Med 2001;2(4):231–5.
[12] Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society–USA Panel. JAMA 2002;288(2):222–35.
[13] Hirsch MS, Brun-Verzinet F, Clotet B, Conway B, Kuritzkes DR, D’Aquilia RT, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society–USA Panel. Clin Infect Dis 2003;37(1):113–28.
[14] Cingolani A, Antinori A, Rizzo MG, Murri R, Ammassari A, Baldini F, et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS 2002;16(3):369–79.
[15] Cohen CJ, Hunt S, Sension M, Farthing C, Conant M, Jacobson S, et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 2002;16(4):579–88.
[16] Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999;353(9171):2195–9.
[17] Arthur RR. Ebola in Africa—discoveries in the past decade. Euro Surveill 2002;7(3):33–6.

[18] Peters CJ, LeDuc JW. An introduction to Ebola: the virus and the disease. J Infect Dis 1999;179(Suppl 1):ix–xvi.

[19] Le Guenno B, Formentry P, Wyers M, Gounon P, Walker F, Boesch C. Isolation and partial characterisation of a new strain of Ebola virus. Lancet 1995;345(8960):1271–4.

[20] Turell MJ, Bressler DS, Rossi CA. Short report: lack of virus replication in arthropods after intrathoracic inoculation of Ebola Reston virus. Am J Trop Med Hyg 1996;55(1): 89–90.

[21] Reiter P, Turell M, Coleman R, Miller B, Maupin G, Liz J, et al. Field investigations of an outbreak of Ebola hemorrhagic fever, Kikwit, Democratic Republic of the Congo, 1995: arthropod studies. J Infect Dis 1999;179(Suppl 1):S148–54.

[22] Geisbert TW, Hensley LE, Jahrling PB, Larsen T, Geisbert JB, Paragas J, et al. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 2003;362(9400):1953–8.

[23] Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344(10):699–709.

[24] Geisbert JB, Hensley LE, Jahrling PB, Anderson KA. Assessment of protective immunity conferred by recombinant vaccinia viruses to guinea pigs challenged with Ebola virus. In: Brown F, Burton D, Norrby E, Mekalanos J, Doherty P, editors. Vaccines '97. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 1997. p. 87–92.

[25] Gilligan KJ, Geisbert JB, Jarhling PB, Anderson KA. Assessment of protective immunity conferred by recombinant vaccinia viruses to guinea pigs challenged with Ebola virus. In: Brown F, Burton D, Norrby E, Mekalanos J, Doherty P, editors. Vaccines '97. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 1997. p. 87–92.

[26] Gilligan KJ, Geisbert JB, Jarhling PB, Anderson KA. Assessment of protective immunity conferred by recombinant vaccinia viruses to guinea pigs challenged with Ebola virus. In: Brown F, Burton D, Norrby E, Mekalanos J, Doherty P, editors. Vaccines '97. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 1997. p. 87–92.

[27] Hensley LE, Jahrling PB, Anderson KA. Assessment of protective immunity conferred by recombinant vaccinia viruses to guinea pigs challenged with Ebola virus. In: Brown F, Burton D, Norrby E, Mekalanos J, Doherty P, editors. Vaccines '97. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 1997. p. 87–92.

[28] Geisbert JB, Hensley LE, Jahrling PB, Anderson KA. Assessment of protective immunity conferred by recombinant vaccinia viruses to guinea pigs challenged with Ebola virus. In: Brown F, Burton D, Norrby E, Mekalanos J, Doherty P, editors. Vaccines '97. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 1997. p. 87–92.
[36] Jezek Z, Szczeniowski MY, Muyembe-Tamfum JJ, McCormick JB, Heymann DL. Ebola between outbreaks: intensified Ebola hemorrhagic fever surveillance in the Democratic Republic of the Congo, 1981–1985. J Infect Dis 1999;179(Suppl 1):S60–4.

[37] Bray M. Defense against filoviruses used as biological weapons. Antiviral Res 2003; 57(1–2):53–60.

[38] Alibek K, Handelman S. Biohazard: the chilling true story of the largest covert biological weapons program in the world—told from inside by the man who ran it. New York: Random House; 1999.

[39] Lee HW, Lee PW, Johnson KM. Isolation of the etiologic agent of Korean Hemorrhagic fever. J Infect Dis 1978;137(3):298–308.

[40] Chapman LE, Khabbaz RF. Etiology and epidemiology of the Four Corners hantavirus outbreak. Infect Agents Dis 1994;3(5):234–44.

[41] Hjelte B, Torrez-Martinez N, Koster FT, Jay M, Ascher MS, Brown T, et al. Epidemiologic linkage of rodent and human hantavirus genomic sequences in case investigations of hantavirus pulmonary syndrome. J Infect Dis 1996;173(4):781–6.

[42] Nemirov K, Lundkvist A, Vaheri A, Plyusnin A. Adaptation of Puumala hantavirus to cell culture is associated with point mutations in the coding region of the L segment and in the noncoding regions of the S segment. J Virol 2003;77(16):8793–800.

[43] Plyusnin A, Cheng Y, Lehvaslaiho H, Vaheri A. Quasispecies in wild-type tula hantavirus populations. J Virol 1996;70(12):9060–3.

[44] Henderson WW, Monroe MC, St Jeor SC, Thayer WP, Rowe JE, Peters CJ, et al. Naturally occurring Sin Nombre virus genetic reassortants. Virology 1995;214(2):602–10.

[45] Klempa B, Schmidt HA, Ulrich R, Kaluz S, Labuda M, Meisel H, et al. Genetic interaction between distinct Dobrava hantavirus subtypes in Apodemus agrarius and A. flavicollis in nature. J Virol 2003;77(1):804–9.

[46] Sibold C, Meisel H, Kruger DH, Labuda M, Lysy J, Kozuch O, et al. Recombination in Tula hantavirus evolution: analysis of genetic lineages from Slovakia. J Virol 1999;73(1):667–75.

[47] Glass GE, Johnson JS, Hodenbach GA, Disalvo CL, Peters CJ, Childs JE, et al. Experimental evaluation of rodent exclusion methods to reduce hantavirus transmission to humans in rural housing. Am J Trop Med Hyg 1997;56(4):359–64.

[48] Plyusnin A. Genetics of hantaviruses: implications to taxonomy. Arch Virol 2002;147(4):665–82.

[49] Lednicky JA. Hantaviruses. a short review. Arch Pathol Lab Med 2003;127(1):30–5.

[50] Peters CJ, Simpson GL, Levy H. Spectrum of hantavirus infection: hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome. Annu Rev Med 1999;50:531–45.

[51] Howard MJ, Doyle TJ, Koster FT, Zaki SR, Khan AS, Petersen EA, et al. Hantavirus pulmonary syndrome in pregnancy. Clin Infect Dis 1999;29(6):1538–44.

[52] Lloyd G, Jones N. Infection of laboratory workers with hantavirus acquired from immunocytomas propagated in laboratory rats. J Infect Dis 1986;12(2):117–25.

[53] Prebensen D. Nephropathia Epidemica infection during first trimester of pregnancy—normal fetal outcome. Acta Obstet Gynecol Scand 1997;76(9):884–5.

[54] Toro J, Vega JD, Khan AS, Mills JN, Padula P, Terry W, et al. An outbreak of hantavirus pulmonary syndrome, Chile, 1997. Emerg Infect Dis 1998;4(4):687–94.

[55] Padula PJ, Edelstein A, Miguel SD, Lopez NM, Rossi CM, Rabinovich RD. Hantavirus pulmonary syndrome outbreak in Argentina: molecular evidence for person-to-person transmission of Andes virus. Virology 1998;241(2):323–30.

[56] Peters CJ, Khan AS. Hantavirus pulmonary syndrome: the new American hemorrhagic fever. Clin Infect Dis 2002;34(9):1224–31.

[57] Huggins JW, Hsiang CM, Cosgriff TM, Guang MY, Smith JI, Wu ZO, et al. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous...
ribavirin therapy of hemorrhagic fever with renal syndrome. J Infect Dis 1991;164(6): 1119–27.

[58] Graziano KL, Tempest B. Hantavirus pulmonary syndrome: a zebra worth knowing. Am Fam Physician 2002;66(6):1015–20.

[59] Ferres M, Vial P. Hantavirus infection in children. Curr Opin Pediatr 2004;16(1):70–5.

[60] Chapman LE, Mertz GJ, Peters CJ, Jolson HM, Khan AS, Ksiazek TG, et al. Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Ribavirin Study Group. Antivir Ther 1999;4(4):211–9.

[61] Gavrilovskaya IN, Shepley M, Shaw R, Ginsberg MH, Mackow ER. Beta3 integrins mediate the cellular entry of hantaviruses that cause respiratory failure. Proc Natl Acad Sci U S A 1998;95(12):7074–9.

[62] Mackow ER, Gavrilovskaya IN. Cellular receptors and hantavirus pathogenesis. Curr Top Microbiol Immunol 2001;256:91–115.

[63] Mori M, Rothman AL, Kurane I, Montoya JM, Nolte KB, Norman JE, et al. High levels of cytokine-producing cells in the lung tissues of patients with fatal hantavirus pulmonary syndrome. J Infect Dis 1999;179(2):295–302.

[64] Ennis FA, Cruz J, Spiropoulou CF, Waite D, Peters CJ, Nichol ST, et al. Hantavirus pulmonary syndrome: CD8⁺ and CD4⁺ cytotoxic T lymphocytes to epitopes on Sin Nombre virus nucleocapsid protein isolated during acute illness. Virology 1997;238(2):380–90.

[65] Wimer BM. Implications of the analogy between recombinant cytokine toxicities and manifestations of hantavirus infections. Cancer Biother Radiopharm 1998;13(3):193–207.

[66] Padula PJ, Colavecchia SB, Martinez VP, Gonzalez Della Valle MO, Edelstein A, Miguel SD, et al. Genetic diversity, distribution, and serological features of hantavirus infection in five countries in South America. J Clin Microbiol 2000;38(8):3029–35.

[67] Elgh F, Lundkvist A, Alexeyev OA, Stenlund H, Avsic-Zupanc T, Hjelle B, et al. Serological diagnosis of hantavirus infections by an enzyme-linked immunosorbent assay based on detection of immunoglobulin G and M responses to recombinant nucleocapsid proteins of five viral serotypes. J Clin Microbiol 1997;35(5):1122–30.

[68] Lundkvist A, Cheng Y, Sjolander KB, Niklasson B, Vaheri A, Plyusnin A. Cell culture adaptation of Puumala hantavirus changes the infectivity for its natural reservoir, Cletethionomys glareolus, and leads to accumulation of mutants with altered genomic RNA S segment. J Virol 1997;71(12):9515–23.

[69] Murray K, Selleck P, Hooper P, Hyatt A, Gould A, Gleeson L, et al. A morbillivirus that caused fatal disease in horses and humans. Science 1995;268(5207):94–7.

[70] Chua KB, Bellini WJ, Rota PA, Harcourt BH, Tamin A, Lam SK, et al. Nipah virus: a recently emergent deadly paramyxovirus. Science 2000;288(5470):1432–5.

[71] Wang L, Harcourt BH, Yu M, Tamin A, Rota PA, Bellini WJ, et al. Molecular biology of Hendra and Nipah viruses. Microbes Infect 2001;3(4):279–87.

[72] Selvey LA, Wells RM, McCormack JG, Ansford AJ, Murray K, Rogers RJ, et al. Infection of humans and horses by a newly described morbillivirus. Med J Aust 1995;162(12):642–5.

[73] O'Sullivan JD, Allworth AM, Paterson DL, Snow TM, Boots R, Gleeson LJ, et al. Fatal encephalitis due to novel paramyxovirus transmitted from horses. Lancet 1997;349(9045):93–5.

[74] Hooper P, Zaki S, Daniels P, Middleton D. Comparative pathology of the diseases caused by Hendra and Nipah viruses. Microbes Infect 2001;3(4):315–22.

[75] Field H, Young P, Yob JM, Mills J, Hall L, Mackenzie J. The natural history of Hendra and Nipah viruses. Microbes Infect 2001;3(4):307–14.

[76] Chua KB, Goh KJ, Wong KT, Kamarulzaman A, Tan PS, Ksiazek TG, et al. Fatal encephalitis due to Nipah virus among pig-farmers in Malaysia. Lancet 1999;354(9186):1257–9.
[77] Goh KJ, Tan CT, Chew NK, Tan PS, Kamarulzaman A, Sarji SA, et al. Clinical features of Nipah virus encephalitis among pig farmers in Malaysia. N Engl J Med 2000;342(17):1229–35.

[78] Tan CT, Goh KJ, Wong KT, Sarji SA, Chua KB, Chew NK, et al. Relapsed and late-onset Nipah encephalitis. Ann Neurol 2002;51(6):703–8.

[79] Enserink M. Emerging infectious diseases. Nipah virus (or a cousin) strikes again. Science 2004;303(5661):1121.

[80] Daniels P, Ksiazek T, Eaton BT. Laboratory diagnosis of Nipah and Hendra virus infections. Microbes Infect 2001;3(4):289–95.

[81] Lam SK. Nipah virus—a potential agent of bioterrorism? Antiviral Res 2003;57(1–2):113–9.

[82] Centers for Disease Control. Bioterrorism agents/diseases. Available at: http://www.bt.cdc.gov/agent/agentlist-category.asp. Accessed March 23, 2004.

[83] Chong HT, Kamarulzaman A, Tan CT, Goh KJ, Thayaparan T, Kunjapan SR, et al. Treatment of acute Nipah encephalitis with ribavirin. Ann Neurol 2001;49(6):810–3.

[84] Guillaume V, Contamin H, Loth P, Georges-Courbot MC, Lefevre A, Marianneau P, et al. Nipah virus: vaccination and passive protection studies in a hamster model. J Virol 2004;78(2):834–40.

[85] van den Hoogen BG, de Jong JC, Groen J, Kuiken T, de Groot R, Fouchier RA, et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med 2001;7(6):719–24.

[86] Ebihara T, Endo R, Kikuta H, Ishiguro N, Ishiko H, Kobayashi K. Comparison of the seroprevalence of human metapneumovirus and human respiratory syncytial virus. J Med Virol 2004;72(2):304–6.

[87] Maggi F, Pifferi M, Vatteroni M, Fornai C, Tempestini E, Anzilotti S, et al. Human metapneumovirus associated with respiratory tract infections in a 3-year study of nasal swabs from infants in Italy. J Clin Microbiol 2003;41(7):2987–91.

[88] Stockton J, Stephenson I, Fleming D, Zambon M. Human metapneumovirus as a cause of community-acquired respiratory illness. Emerg Infect Dis 2002;8(9):897–901.

[89] Cuevas LE, Nasser AM, Dove W, Gurgel RQ, Greensill J, Hart CA. Human metapneumovirus and respiratory syncytial virus. Brazil. Emerg Infect Dis 2003;9(12):1626–8.

[90] Viazov S, Ratjen F, Scheidhauer R, Fiedler M, Roggendorf M. High prevalence of human metapneumovirus infection in young children and genetic heterogeneity of the viral isolates. J Clin Microbiol 2003;41(7):3043–5.

[91] Chan PK, Tam JS, Lam CW, Chan E, Wu A, Li CK, et al. Human metapneumovirus detection in patients with severe acute respiratory syndrome. Emerg Infect Dis 2003;9(9):1058–63.

[92] Greensill J, McNamara PS, Dove W, Flanagan B, Smyth RL, Hart CA. Human metapneumovirus in severe respiratory syncytial virus bronchiolitis. Emerg Infect Dis 2003;9(3):372–5.

[93] Falsey AR, Erdman D, Anderson LJ, Walsh EE. Human metapneumovirus infections in young and elderly adults. J Infect Dis 2003;187(5):785–90.

[94] Williams JV, Harris PA, Tollefson SJ, Halburnt-Rush LL, Pingsterhaus JM, Edwards KM, et al. Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. N Engl J Med 2004;350(5):443–50.

[95] Boivin G, Abed Y, Pelletier G, Ruel L, Moisan D, Cote S, et al. Virological features and clinical manifestations associated with human metapneumovirus: a new paramyxovirus responsible for acute respiratory-tract infections in all age groups. J Infect Dis 2002;186(9):1330–4.

[96] Boivin G, De Serres G, Cote S, Gilca R, Abed Y, Rochette L, et al. Human metapneumovirus infections in hospitalized children. Emerg Infect Dis 2003;9(6):634–40.
[97] Maertzdorf J, Wang CK, Brown JB, Quinto JD, Chu M, De Graaf M, et al. Real-time reverse transcriptase PCR assay for detection of human metapneumoviruses from all known genetic lineages. J Clin Microbiol 2004;42(3):981–6.
[98] Guan Y, Peiris JS, Lipatov AS, Ellis TM, Dyrting KC, Krauss S, et al. Emergence of multiple genotypes of H5N1 avian influenza viruses in Hong Kong SAR. Proc Natl Acad Sci U S A 2002;99(13):8950–5.
[99] Alexander DJ. Report on avian influenza in the Eastern Hemisphere during 1997–2002. Avian Dis 2003;47(Suppl 3):792–7.
[100] Smirnov YA, Gitelman AK, Govorkova EA, Lipatov AS, Kaverin NV. Influenza H5 virus escape mutants: immune protection and antibody production in mice. Virus Res 2004;99(2):205–8.
[101] Cases of influenza A (H5N1)—Thailand, 2004. MMWR Morb Mortal Wkly Rep 2004;53(5):100–3.
[102] Outbreaks of avian influenza A (H5N1) in Asia and interim recommendations for evaluation and reporting of suspected cases—United States, 2004. MMWR Morb Mortal Wkly Rep 2004;53(5):97–100.
[103] Fouchier RA, Schneeberger PM, Rozendaal FW, Broekman JM, Kemink SA, Munster V, et al. Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc Natl Acad Sci U S A 2004;101(5):1356–61.
[104] Koopmans M, Wilbrink B, Conyn M, Natrop G, van der Nat H, Vennema H, et al. Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet 2004;363(9409):587–93.
[105] Banks J, Plowright L. Additional glycosylation at the receptor binding site of the hemagglutinin (HA) for H5 and H7 viruses may be an adaptation to poultry hosts, but does it influence pathogenicity? Avian Dis 2003;47(Suppl 3):942–50.
[106] Senne DA, Suarez DL, Pedersen JC, Panigrahy B. Molecular and biological characteristics of H5 and H7 avian influenza viruses in live-bird markets of the northeastern United States, 1994–2001. Avian Dis 2003;47(Suppl 3):898–904.
[107] Spackman E, Senne DA, Davison S, Suarez DL. Sequence analysis of recent H7 avian influenza viruses associated with three different outbreaks in commercial poultry in the United States. J Virol 2003;77(24):13399–402.
[108] Webby RJ, Woolcock PR, Krauss SL, Walker DB, Chin PS, Shortridge KF, et al. Multiple genotypes of nonpathogenic H6N2 influenza viruses isolated from chickens in California. Avian Dis 2003;47(Suppl 3):905–10.
[109] Cameron KR, Gregory V, Banks J, Brown IH, Alexander DJ, Hay AJ, et al. H9N2 subtype influenza A viruses in poultry in Pakistan are closely related to the H9N2 viruses responsible for human infection in Hong Kong. Virology 2000;278(1):36–41.
[110] Peiris M, Yuen KY, Leung CW, Chan KH, Ip PL, Lai RW, et al. Human infection with influenza H9N2. Lancet 1999;354(9182):916–7.
[111] Peiris JS, Guan Y, Markwell D, Ghose P, Webster RG, Shortridge KF. Cocirculation of avian H9N2 and contemporary “human” H3N2 influenza A viruses in pigs in southeastern China: potential for genetic reassortment? J Virol 2001;75(20):9679–86.
[112] Li KS, Xu KM, Peiris JS, Poon LL, Yu KZ, Yuen KY, et al. Characterization of H9 subtype influenza viruses from the ducks of southern China: a candidate for the next influenza pandemic in humans? J Virol 2003;77(12):6988–94.
[113] Tumpey TM, Garcia-Sastre A, Taubenberger JK, Palese P, Swayne DE, Basler CF. Pathogenicity and immunogenicity of influenza viruses with genes from the 1918 pandemic virus. Proc Natl Acad Sci U S A 2004;101(9):3166–71.
[114] Ladnyj ID, Ziegler P, Kima E. A human infection caused by monkeypox virus in Basankusu Territory, Democratic Republic of the Congo. Bull World Health Organ 1972;46(5):593–7.
von Magnus P, Anderson EK, Petersen KB, Birch-Anderson A. A pox-like disease in cynomolgus monkeys. Acta Pathol Microbiol Scand 1959;46:156–76.

Update: multistate outbreak of monkeypox—Illinois, Indiana, Kansas, Missouri, Ohio, and Wisconsin, 2003. MMWR Morb Mortal Wkly Rep 2003;52(27):642–6.

Reed KD, Melski JW, Graham MB, Regnery RL, Sotir MJ, Wegner MV, et al. The detection of monkeypox in humans in the Western Hemisphere. N Engl J Med 2004;350(4):342–50.

Jezek Z, Szczeniowski M, Paluku KM, Mutombo M. Human monkeypox: clinical features of 282 patients. J Infect Dis 1987;156(2):293–8.

Breman JG, Henderson DA. Diagnosis and management of smallpox. N Engl J Med 2002;346(17):1300–8.

Breman JG, Kalisa R, Steniowski MV, Zanotto E, Gromyko AI, Arita I. Human monkeypox, 1970–79. Bull World Health Organ 1980;58(2):165–82.

Hanrahan JA, Jakubowycz M, Davis BR. A smallpox false alarm. N Engl J Med 2003;348(5):467–8 [discussion: 467–8].

Breman JG. Monkeypox: an emerging infection for humans? In: Scheld WM, Craig WA, Hughes JM, editors. Emerging infections. 4th edition. Washington, DC: ASM Press; 2000. p. 45–67.

Damon IK, Esposito JJ. Poxviruses that infect humans. In: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolker MH, editors. Manual of clinical microbiology. 8th edition. Washington, DC: ASM Press; 2003. p. 1583–91.

Espy MJ, Cockerill IF, Meyer RF, Bowen MD, Poland GA, Hadfield TL, et al. Detection of smallpox virus DNA by LightCycler PCR. J Clin Microbiol 2002;40(6):1985–8.

Laassri M, Chizhikov V, Mikheev M, Shchelkunov S, Chumakov K. Detection and discrimination of orthopoxviruses using microarrays of immobilized oligonucleotides. J Virol Methods 2003;112(1–2):67–78.

Lapa S, Mikheev M, Shchelkunov S, Mikhailovich V, Sobolev A, Blinov V, et al. Species-level identification of orthopoxviruses with an oligonucleotide microchip. J Clin Microbiol 2002;40(3):753–7.

Di Giulio DB, Eckburg PB. Human monkeypox: an emerging zoonosis. Lancet Infect Dis 2004;4(1):15–25.

De Clercq E. Cidofovir in the treatment of poxvirus infections. Antiviral Res 2002;55(1):1–13.

Heymann DL, Szczeniowski M, Esteves K. Re-emergence of monkeypox in Africa: a review of the past six years. Br Med Bull 1998;54(3):693–702.

Zaucha GM, Jahrling PB, Geisbert TW, Swaarengen JR, Hensley L. The pathology of experimental aerosolized monkeypox virus infection in cynomolgus monkeys (Macaca fascicularis). Lab Invest 2001;81(12):1581–600.

Gubser C, Hue S, Kellam P, Smith GL. Poxvirus genomes: a phylogenetic analysis. J Gen Virol 2004;85(Pt 1):105–17.

Shchelkunov SN, Totmenin AV, Safronov PF, Mikheev MV, Gutorov VV, Ryazankina OI, et al. Analysis of the monkeypox virus genome. Virology 2002;297(2):172–94.

Jackson RJ, Ramsay AJ, Christensen CD, Beaton S, Hall DF, Ramshaw IA. Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. J Virol 2001;75(3):1205–10.

Stich A, Meyer H, Kohler B, Fleischer K. Tanapox: first report in a European traveller and identification by PCR. Trans R Soc Trop Med Hyg 2002;96(2):178–9.

Dhar AD, Werchniak AE, Li Y, Brennicker JB, Goldsmith CS, Kline R, et al. Tanapox infection in a college student. N Engl J Med 2004;350(4):361–6.

Baxby D, Bennett M. Poxvirus zoonoses. J Med Microbiol 1997;46(1):17–20,28–33.

Diven DG. An overview of poxviruses. J Am Acad Dermatol 2001;44(1):1–16.

Knight JC, Novembre FJ, Brown DR, Goldsmith CS, Esposito JJ. Studies on Tanapox virus. Virology 1989;172(1):116–24.
[139] Brunetti CR, Amano H, Ueda Y, et al. Complete genomic sequence and comparative
analysis of the tumorigenic poxvirus Yaba monkey tumor virus. J Virol 2003;77(24):
13335–47.

[140] Lee HJ, Essani K, Smith GL. The genome sequence of Yaba-like disease virus,
a yatapoxvirus. Virology 2001;281(2):170–92.

[141] Downie AW, Espana C. Comparison of Tanapox virus and Yaba-like viruses causing
epidemic disease in monkeys. J Hyg (Lond) 1972;70(1):23–32.

[142] McNulty WP Jr, Lobitz WC Jr, Hu F, Maruffo CA, Hall AS. A pox disease in
monkeys transmitted to man. Clinical and histological features. Arch Dermatol 1968;
97(3):286–93.

[143] Henderson D, Moss B. Smallpox and vaccinia. In: Plotkin S, Orenstein S, Zorab R,
editors. Vaccines. 3rd edition. Philadelphia: Harcourt Brace and Co.; 1999. p. 74–97.

[144] Fenner F. Adventures with poxviruses of vertebrates. FEMS Microbiol Rev 2000;24(2):
123–33.

[145] Keith KA, Hitchcock MJ, Lee WA, Holy A, Kern ER. Evaluation of nucleoside
phosphonates and their prodrugs for inhibition of orthopoxvirus replication.
Antimicrob Agents Chemother 2003;47(7):2193–8.

[146] Breman JG, Henderson DA. Poxvirus dilemmas—monkeypox, smallpox, and biologic
terrorism. N Engl J Med 1998;339(8):556–9.

[147] Bonilla-Guerrero R, Poland GA. Smallpox vaccines: current and future. J Lab Clin Med
2003;142(4):252–7.

[148] Clements CJ. Mass psychogenic illness after vaccination. Drug Saf 2003;26(9):599–604.

[149] Cardiac deaths after a mass smallpox vaccination campaign—New York City, 1947.
MMWR Morb Mortal Wkly Rep 2003;52(39):933–6.

[150] Gellman B. 4 nations thought to possess smallpox. Washington Post, November 5, 2002.

[151] Nitsche A, Ellerbrok H, Pauli G. Detection of orthopoxvirus DNA by real-time PCR and
identification of variola virus DNA by melting analysis. J Clin Microbiol 2004;42(3):
1207–13.

[152] Sofi Ibrahim M, Kulesh DA, Saleh SS, Damon IK, Esposito JJ, Schmaljohn AL, et al.
Real-time PCR assay to detect smallpox virus. J Clin Microbiol 2003;41(8):3835–9.

[153] Marra MA, Jones SJ, Astell CR, Holt RA, Brooks-Wilson A, Butterfield YS, et al. The
genome sequence of the SARS-associated coronavirus. Science 2003;300(5624):1399–404.

[154] Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, et al. A novel coronavi-
sus associated with Severe Acute Respiratory Syndrome. N Engl J Med 2003;348(20):
1953–66.

[155] Peiris JS, Yuen KY, Osterhaus AD, Stohr K. The Severe Acute Respiratory Syndrome.
N Engl J Med 2003;349(25):2431–41.

[156] Monto AS, Lim SK. The Tecumseh study of respiratory illness. VI. Frequency of and
relationship between outbreaks of coronavirus infection. J Infect Dis 1974;129(3):271–6.

[157] Parry J. WHO confirms SARS in Chinese journalist. BMJ 2004;328(7431):65.

[158] Stavrinides J, Guttmann DS. Mosaic evolution of the Severe Acute Respiratory Syndrome
coronavirus. J Virol 2004;78(1):76–82.

[159] Guan Y, Peiris J, Zheng B, Poon L, Chan K, Zeng F, et al. Molecular epidemiology of the
novel coronavirus that causes Severe Acute Respiratory Syndrome. Lancet 2004;
363(9403):99–104.

[160] Severe Acute Respiratory Syndrome—Singapore, 2003. MMWR Morb Mortal Wkly Rep.
2003;52(18):405–11.

[161] Riley S, Fraser C, Donnelly CA, Ghani AC, Abu-Raddad LJ, Hedley AJ, et al.
Transmission dynamics of the etiological agent of SARS in Hong Kong: impact of public
health interventions. Science 2003;300(5627):1961–6.

[162] Grant PR, Garson JA, Tedder RS, Chan PK, Tam JS, Sung JJ. Detection of SARS
coronavirus in plasma by real-time RT-PCR. N Engl J Med 2003;349(25):
2468–9.
Ng LF, Wong M, Koh S, Ooi EE, Tang KF, Leong HN, et al. Detection of Severe Acute Respiratory Syndrome coronavirus in blood of infected patients. J Clin Microbiol 2004;42(1):347–50.

Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt GM, et al. A major outbreak of Severe Acute Respiratory Syndrome in Hong Kong. N Engl J Med 2003;348(20):1986–94.

Booth CM, Matukas LM, Tomlinson GA, Rachlis AR, Rose DB, Dwosh HA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 2003;289(21):2801–9.

Tsang KW, Ho PL, Ooi GC, Yee WK, Wang T, Chan-Yeung M, et al. A cluster of cases of Severe Acute Respiratory Syndrome in Hong Kong. N Engl J Med 2003;348(20):1977–85.

Fujii T, Nakamura T, Iwamoto A. Current concepts in SARS treatment. J Infect Chemother 2004;10(1):1–7.

Jones BM, Ma ES, Peiris JS, Wong PC, Ho JC, Lam B, et al. Prolonged disturbances of in vitro cytokine production in patients with Severe Acute Respiratory Syndrome (SARS) treated with ribavirin and steroids. Clin Exp Immunol 2004;135(3):467–73.

Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004;59(3):252–6.

World Health Organization issues emergency travel advisory. March 15, 2003.

Tang P, Louie M, Richardson SE, Smieja M, Simor AE, Jamieson F, et al. Interpretation of diagnostic laboratory tests for Severe Acute Respiratory Syndrome: the Toronto experience. CMAJ 2004;170(1):47–54.

Poon LL, Chan KH, Wong OK, Cheung TK, Ng I, Zheng B, et al. Detection of SARS coronavirus in patients with Severe Acute Respiratory Syndrome by conventional and real-time quantitative reverse transcription-PCR assays. Clin Chem 2004;50(1):67–72.

Yam WC, Chan KH, Poon LL, Guan Y, Yuen KY, Seto WH, et al. Evaluation of real-time reverse transcription-PCR assays for rapid diagnosis of Severe Acute Respiratory Syndrome associated with a novel coronavirus. J Clin Microbiol 2003;41(10):4521–4.

WHO post-outbreak biosafety guidelines for handling of SARS-CoV specimens and cultures. December 18, 2003.

Enserink M. Infectious diseases. Singapore lab faulted in SARS case. Science 2003;301(5641):1824.

Normile D. Infectious diseases. Second lab accident fuels fears about SARS. Science 2004;303(5654):26.

Smithburn KC, Hughes TP, Burke AW, Paul JH. Neurotropic virus isolated from blood of native of Uganda. Am J Trop Med 1940;20:471–92.

Sampathkumar P. West Nile virus: epidemiology, clinical presentation, diagnosis, and prevention. Mayo Clin Proc 2003;78(9):1137–43 [quiz: 1144].

Lanciotti RS, Roehrig JT, Deubel V, Smith J, Parker M, Steele K, et al. Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States. Science 1999;286(5448):2333–7.

Turell MJ, Sardelis MR, Dohm DJ, O'Guinn ML. Potential North American vectors of West Nile virus. Ann N Y Acad Sci 2001;951:317–24.

Campbell GL, Marfin AA, Lanciotti RS, Gubler DJ. West Nile virus. Lancet Infect Dis 2002;2(9):519–29.

Marfin AA, Petersen LR, Eidson M, Miller J, Hadler J, Farello C, et al. Widespread West Nile virus activity, eastern United States, 2000. Emerg Infect Dis 2001;7(4):730–5.

Malkinson M, Banet C, Weisman Y, Pokamunski S, King R, Drouet MT, et al. Introduction of West Nile virus in the Middle East by migrating white storks. Emerg Infect Dis 2002;8(4):392–7.
Update: investigations of West Nile virus infections in recipients of organ transplantation and blood transfusion—Michigan, 2002. MMWR Morb Mortal Wkly Rep 2002;51(39):879.

Centers for Disease Control and Prevention. Laboratory-acquired West Nile virus infections—United States, 2002. JAMA 2003;289(4):414–5.

Feldmann H, Jones S, Klenk HD, Schnittler HJ. Ebola virus: from discovery to vaccine. Nat Rev Immunol 2003;3(8):677–85.

Centers for Disease Control and Prevention. Investigations of West Nile virus infections in recipients of blood transfusions. JAMA 2002;288(20):2535–6.

Centers for Disease Control and Prevention. Possible West Nile virus transmission to an infant through breast-feeding—Michigan, 2002. JAMA 2002;288(16):1976–7.

Centers for Disease Control and Prevention. West Nile virus activity—United States, September 26–October 2, 2002, and investigations of West Nile virus infections in recipients of blood transfusion and organ transplantation. JAMA 2002;288(16):1975–6.

Iwamoto M, Jernigan DB, Gausch A, Trepka MJ, Blackmore CG, Hellinger WC, et al. Transmission of West Nile virus from an organ donor to four transplant recipients. N Engl J Med 2003;348(22):2196–203.

Detection of West Nile virus in blood donations—United States, 2003. MMWR Morb Mortal Wkly Rep 2003;52(32):769–72.

Harrington T, Kuehnert MJ, Kamel H, Lanciotti RS, Hand S, Currier M, et al. West Nile virus infection transmitted by blood transfusion. Transfusion 2003;43(8):1018–22.

Spigland I, Jasinska-Klingberg W, Hofshi E, Goldblum N. Clinical and laboratory observations in an outbreak of West Nile fever in Israel in 1957. Harefuah 1958;54(11):275–80 [English and French abstracts: 280–1].

Asnis DS, Conetta R, Teixeira AA, Waldman G, Sampson BA. The West Nile Virus outbreak of 1999 in New York: the Flushing Hospital experience. Clin Infect Dis 2000;30(3):413–8.

Petersen LR, Marfin AA. West Nile virus: a primer for the clinician. Ann Intern Med 2002;137(3):173–9.

Klein C, Kimiagar I, Pollak L, Gandelman-Marton R, Itzhaki A, Milo R, et al. Neurological features of West Nile virus infection during the 2000 outbreak in a regional hospital in Israel. J Neurol Sci 2002;200(1–2):63–6.

Weiss D, Carr D, Kellachan J, Tan C, Phillips M, Bresnitz E, et al. Clinical findings of West Nile virus infection in hospitalized patients, New York and New Jersey, 2000. Emerg Infect Dis 2001;7(4):654–8.

Chowers MY, Lang R, Nassar F, Ben-David D, Giladi M, Rubinshtein E, et al. Clinical characteristics of the West Nile fever outbreak, Israel, 2000. Emerg Infect Dis 2001;7(4):675–8.

Nash D, Labowitz A, Maldin B, et al. A follow-up study of persons infected with West Nile virus during a 1999 outbreak in the New York City area [abstract]. Presented at the 39th Annual Meetings of the Infectious Diseases Society of America. San Francisco, 2001.

Deubel V, Fiette L, Gounon P, Drouet MT, Khun H, Huerre M, et al. Variations in biological features of West Nile viruses. Ann N Y Acad Sci 2001;951:195–206.

Brinton MA. The molecular biology of West Nile Virus: a new invader of the western hemisphere. Annu Rev Microbiol 2002;56:371–402.

Sampson BA, Armbrustmacher V. West Nile encephalitis: the neuropathology of four fatalities. Ann N Y Acad Sci 2001;951:172–8.

Cantile C, Del Piero F, Di Guardo G, Arispici M. Pathologic and immunohistochemical findings in naturally occurring West Nile virus infection in horses. Vet Pathol 2001;38(4):414–21.

Steele KE, Linn MJ, Schoepf RJ, Komar N, Geisbert TW, Mandrau RM, et al. Pathology of fatal West Nile virus infections in native and exotic birds during the 1999 outbreak in New York City, New York. Vet Pathol 2000;37(3):208–24.
[205] Sampson BA, Nields H, Armbrustmacher V, Asnis DS. Muscle weakness in West Nile encephalitis is due to destruction of motor neurons. Hum Pathol 2003;34(6):628–9.

[206] Tardei G, Ruta S, Chitu V, Rossi C, Tsai TF, Cernescu C. Evaluation of immunoglobulin M (IgM) and IgG enzyme immunoassays in serologic diagnosis of West Nile Virus infection. J Clin Microbiol 2000;38(6):2232–9.

[207] Lanciotti RS, Kerst AJ, Nasci RS, Godsey MS, Mitchell CJ, Savage HM, et al. Rapid detection of West Nile virus from human clinical specimens, field-collected mosquitoes, and avian samples by a TaqMan reverse transcriptase-PCR assay. J Clin Microbiol 2000;38(11):4066–71.

[208] Shimoni Z, Niven MJ, Pitlick S, Bulvik S. Treatment of West Nile virus encephalitis with intravenous immunoglobulin. Emerg Infect Dis 2001;7(4):759.

[209] Jordan I, Briese T, Fischer N, Lau JY, Lipkin WI. Ribavirin inhibits West Nile virus replication and cytopathic effect in neural cells. J Infect Dis 2000;182(4):1214–7.

[210] Anderson JF, Rahal JJ. Efficacy of interferon alpha-2b and ribavirin against West Nile virus in vitro. Emerg Infect Dis 2002;8(1):107–8.

[211] Nipah virus in Bangladesh. WHO Disease Outbreak News. April 20, 2004. Available at: http://www.who.int/csr/don/2004_04_20/en/. Accessed on June 17, 2004.